These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33285109)

  • 1. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
    Alvarado-Cruz I; Mahmoud M; Khan M; Zhao S; Oeck S; Meas R; Clairmont K; Quintana V; Zhu Y; Porciuncula A; Wyatt H; Ma S; Shyr Y; Kong Y; LoRusso PM; Laverty D; Nagel ZD; Schalper KA; Krauthammer M; Sweasy JB
    Biochem Pharmacol; 2021 Feb; 184():114359. PubMed ID: 33285109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
    Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
    J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
    Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
    Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 11. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
    BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 18. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
    Wang Q; Bergholz JS; Ding L; Lin Z; Kabraji SK; Hughes ME; He X; Xie S; Jiang T; Wang W; Zoeller JJ; Kim HJ; Roberts TM; Konstantinopoulos PA; Matulonis UA; Dillon DA; Winer EP; Lin NU; Zhao JJ
    Nat Commun; 2022 May; 13(1):3022. PubMed ID: 35641483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK Inhibition Remodels the Immune Landscape of Mutant
    Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
    Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
    Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
    Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.